Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Consensus Price Target of $10.00 According to Analysts

Key Points

• Analyst sentiment is “Moderate Buy”: Seven analysts cover Autolus, with three Buy, two Strong Buy, one Hold, and one Sell rating; their average 12-month price target is $10.00.
• AUTL opened at $1.28, near its 52-week low of $1.18 and below its 52-week high of $2.58.
• In its latest reported quarter, Autolus posted a loss of $0.15 per share, better than the $0.21 loss analysts expected, and revenue of $45.69 million versus estimates of $38.56 million.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $10.00.

Several research analysts have recently weighed in on AUTL shares. Wall Street Zen upgraded shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, August 16th. HC Wainwright assumed coverage on shares of Autolus Therapeutics in a report on Monday, November 2nd. They issued a "buy" rating on the stock. Finally, Weiss Ratings downgraded shares of Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, November 3rd.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Syncona Portfolio Ltd bought a new position in shares of Autolus Therapeutics during the 2nd quarter worth approximately $26,625,152. Alphabet Inc. acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth approximately $1,117,000. Privium Fund Management B.V. raised its stake in Autolus Therapeutics by 29.2% in the 3rd quarter. Privium Fund Management B.V. now owns 469,490 shares of the company's stock valued at $911,000 after acquiring an additional 106,060 shares during the period. Cetera Investment Advisers raised its stake in Autolus Therapeutics by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company's stock valued at $1,558,000 after acquiring an additional 29,324 shares during the period. Finally, Waverly Advisors LLC bought a new stake in Autolus Therapeutics in the 1st quarter valued at $37,000. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $1.28 on Monday. Autolus Therapeutics has a 1-year low of $1.18 and a 1-year high of $2.58. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04. The firm has a fifty day simple moving average of $1.80 and a 200 day simple moving average of $1.66. The stock has a market capitalization of $340.68 million, a PE ratio of -1.21 and a beta of 2.32.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. On average, research analysts expect that Autolus Therapeutics will post -0.76 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company's approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.